EANS-News: Epigenomics AG / Epigenomics AG to host Press Conference and Analyst Meeting for 2008 Annual Results

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies/press conference

Berlin, Germany and Seattle, WA, U.S.A (euro adhoc) - March 11, 2009
- Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular
diagnostics company will hold its annual press conference and analyst
meeting on Tuesday, March 31, 2009 and present results for the fiscal
year 2008. Geert Nygaard, CEO and Oliver Schacht, CFO will give an
overview of the operational developments as well as provide guidance
for 2009. A conference call with Epigenomics' management will be held
later on the same day.

Press Conference and Analyst Meeting

The press conference and analyst meeting will be conducted in German
and will be held on Tuesday, March 31, 2009 at 10 am to 12 noon CET
at the premises of the Villa Bonn - Frankfurter Gesellschaft für
Handel Industrie und Wirtschaft in Frankfurt am Main:

Villa Bonn
Frankfurter Gesellschaft für Handel Industrie und Wirtschaft
Siesmayerstrasse 12
60323 Frankfurt am Main

Room: Vortragsraum (OG)

Epigenomics asks interested parties to confirm their participation
for the press conference and analyst meeting by Thursday, March 26,
2009 by fax +49 (0)30 24 34 5- 555 or email ir@epigenomics.com.

Conference Call

A conference call will be held on Tuesday, March 31, 2009 at 3 pm to
4 pm CET (9 am to 10 am EST), hosted by Epigenomics' management to
discuss 2008 financial results and outlook for 2009. The conference
call will be conducted in English.

Dial-in number (within Germany.): +49 868 71 790

Dial-in number (outside Germany): +1 212 444 0297

Please dial-in at least 10 minutes prior to commencement of the
conference call.

To follow the presentation, Epigenomics kindly ask all participants
of the call to download the slide set from the company website prior
to the call where it will be made available as a PDF file at 10 am
CET (4 am EST) on the same day.

Internet link:
http://www.epigenomics.com/en/down_loads/corporate_material/

The conference call will be recorded and also made available on the
company website web as a MP3 file after the call.

Internet link:
http://www.epigenomics.com/en/down_loads/corporate_material/

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests in development aim at diagnosing
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the
early detection of colorectal cancer in blood plasma, and further
proprietary DNA methylation biomarkers at various stages of
development for prostate and lung cancer detection in urine, blood
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample
demonstrated continuously highest performance in multiple clinical
studies with in total about 3,500 individuals tested.

For development and global commercialization of in vitro diagnostic
test products, Epigenomics pursues a non-exclusive partnering
strategy. Strategic diagnostics industry partners include Abbott
Molecular, Philips, Sysmex Corporation and Quest Diagnostics
Incorporated for diagnostics test products and services, and QIAGEN
N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research
community can access Epigenomics' portfolio of proprietary DNA
methylation technologies and biomarkers protected by more than 150
patent families through research products, Biomarker Services, IVD
Development Collaborations, and Licensing. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary
in Seattle, WA, U.S.A. For more information, please visit
Epigenomics' website at www.epigenomics.com.

###

Epigenomics' legal disclaimer.

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade